Method for identifying active domains and amino acid residues in polypeptides and hormone variants

- Genentech, Inc.

The invention provides methods for the systematic analysis of the structure and function of polypeptides by identifying active domains which influence the activity of the polypeptide with a target substance. Such active domains are determined by substituting selected amino acid segments of the polypeptide with an analogous polypeptide segment from an analog to the polypeptide. The analog has a different activity with the target substance as compared to the parent polypeptide. The activities of the segment-substituted polypeptides are compared to the same activity for the parent polypeptide for the target. A comparison of such activities provides an indication of the location of the active domain in the parent polypeptide. The invention also provides methods for identifying the active amino acid residues within the active domain of the parent polypeptide. The method comprises substituting a scanning amino acid for one of the amino acid residues within the active domain of the parent polypeptide and assaying the residue-substituted polypeptide so formed with a target substance. The invention further provides polypeptide variants comprising segment-substituted and residue-substituted growth hormones, prolactins and placental lactogens.

Skip to:  ·  Claims  ·  References Cited  · Patent History  ·  Patent History

Claims

1. A method for identifying at least a first unknown active domain in a region of known amino acid sequence of a parent polypeptide, which parent polypeptide has been cloned and has a pre-identified biological activity, said active domain capable of interacting with a first target when said parent polypeptide is in its native-folded form, which interaction is responsible for said biological activity, said method comprising:

(a) comparing amino acid sequence or polypeptide structure in the region of known amino acid sequence of the parent polypeptide with amino acid sequence or polypeptide structure in a region of known amino acid sequence of an analog polypeptide to said parent polypeptide, said analog having at least 15% sequence homology with said parent polypeptide or.alpha.-carbon coordinates within about 2 to about 3.5.ANG. of parent polypeptide.alpha.-carbon coordinates for about 60% or more of the analog sequence, wherein any interaction of said analog with said first target is different from the interaction of said parent polypeptide with said first target;
(b) substituting DNA encoding a first analogous polypeptide segment from said analog into DNA encoding substantially the full-length parent polypeptide and expressing a first segment-substituted polypeptide;
(c) contacting said first segment-substituted polypeptide with said first target to determine the interaction, if any, between said first target and said segment-substituted polypeptide;
(d) repeating steps (b) and (c) using a second analogous polypeptide segment from an analog to said parent polypeptide to form at least a second segment-substituted polypeptide containing said second analogous polypeptide segment, which is different from said first analogous polypeptide segment; and
(e) comparing the difference, if any, between the activity relative to said first target of said parent polypeptide and said first and second segment-substituted polypeptides as an indication of the location of said first unknown active domain in said parent polypeptide.

2. The method of claim 1 wherein said first unknown active domain comprises at least two discontinuous amino acid segments in the primary amino acid sequence of said parent polypeptide.

3. The method of claim 1 wherein at least a first selected polypeptide segment of said parent polypeptide replaced by said first analogous polypeptide segment of said analog contains at least one amino acid residue located on the surface of the native-folded form of said parent polypeptide.

4. The method of claim 3 further comprising repeating steps (b) and (c) to form a plurality of segment-substituted polypeptides that, collectively, contain substitutions of substantially all of the amino acid residues on said surface of said parent polypeptide.

5. The method of claim 1 further comprising repeating steps (b) and (c) to form a plurality of segment-substituted polypeptides that, collectively, contain substitutions of analogous polypeptide segments covering about 15-100% of the amino acid sequence of said parent polypeptide.

6. The method of claim 1 further comprising repeating steps (b) and (c) to form a plurality of segment-substituted polypeptides that, collectively, contain substitutions of analogous polypeptide segments covering about 60-100% of the amino acid sequence of said parent polypeptide.

7. The method of claim 1 further comprising identifying a second unknown active domain of said parent polypeptide, said second active domain interacting with a second target, said method comprising repeating steps (b) through (e) with said second target.

8. The method of claim 1 further comprising identifying at least a first active amino acid residue within said first active domain, said method comprising:

(f) substituting a scanning amino acid for a different first amino acid residue within said first active domain to form a first residue-substituted polypeptide;
(g) contacting said first residue-substituted polypeptide with said first target to determine the interaction, if any, between said first target and said first residue-substituted polypeptide;
(h) repeating steps (f) and (g) to substitute a scanning amino acid for at least a second amino acid residue within said first active domain to form at least a second residue-substituted polypeptide; and
(i) comparing the difference, if any, between the activity relative to said first target of said parent polypeptide and each of said first and second residue-substituted polypeptides as an indication of the location of said first active amino acid residue in said first active domain.

9. The method of claim 8 further comprising repeating steps (b) through (i) with a second target to identity a second active domain and at least one active amino acid residue within said second active domain.

10. The method of claim 9 further comprising the step of substituting an active amino acid residue in said first active domain with a different amino acid to produce a polypeptide variant having a modified interaction with said first target but which retains substantially all of the interaction of said parent polypeptide with said second target.

11. The method of claim 10 further comprising the step of substituting an active amino acid residue in said second active domain with a different amino acid to produce a polypeptide variant having a modified interaction with said second target but which retains the interaction of said parent polypeptide with said first target.

12. The method of claim 9 wherein said first and said second active domains have at least one common active amino acid residue, said method further comprising substituting at least said one common active amino acid residue with a different amino acid to produce a polypeptide variant having modified interactions with each of said first and said second targets.

13. The method of claim 9 wherein said first and said second active domains have at least one common active amino acid residue, said method further comprising substituting at least one amino acid residue in said first active domain, other than said at least one common active amino acid residue, with a different amino acid to produce a polypeptide variant having a modified interaction with said first target.

14. A method for identifying at least one active amino acid residue in a parent polypeptide, which parent polypeptide has been cloned and has a pre-identified biological activity resulting from an interaction with a first target, comprising:

(a) substituting DNA encoding a scanning amino acid for DNA encoding a first amino acid residue at residue number N within DNA encoding substantially the full-length parent polypeptide and expressing an N-substituted polypeptide;
(b) substituting DNA encoding a scanning amino acid for each of the amino acid residues at residue numbers N+1 and N-1 to said first residue within DNA encoding substantially the full-length parent polypeptide and expressing N+1- and N-1-substituted polypeptides, respectively;
(c) contacting each of said substituted polypeptides expressed in steps (a) and (b) with said first target to determine the interaction, if any, between said first target and said substituted polypeptides; and
(d) comparing the difference, if any, between the activity relative to said first target of said parent polypeptide and said substituted polypeptides as an indication of the location of said active amino acid residue.

15. The method of claim 14 wherein residue N is a suspected active amino acid residue and steps (b) through (d) are repeated until at least four consecutive residues are identified wherein substitution of a scanning amino acid at each of said four conservative residues has less than a two-fold effect on activity with said first target as compared to said parent polypeptide.

16. The method of claim 14 wherein said parent polypeptide is selected from the group consisting of human growth hormone, human placental lactogen, and human prolactin.

17. The method of claim 14 wherein at least one of said scanning amino acids is an isosteric amino acid.

18. The method of claim 14 wherein the same scanning amino acid is employed in steps (a) and (b), and said scanning amino acid is a neutral amino acid.

19. The method of claim 18 wherein said neutral amino acid is selected from the group consisting of alanine, serine, glycine, and cysteine.

20. The method of claim 19 wherein said scanning amino acid is alanine.

21. The method of claim 14 wherein said parent polypeptide is a hormone and said activity is measured in an in vitro assay using a soluble hormone receptor.

22. The method of claim 21 wherein said hormone is human growth hormone and said soluble hormone receptor is shGHr.

23. The method of claim 21 wherein said hormone is human growth hormone and said soluble hormone receptor is shPRLr.

24. The method of claim 14 wherein said interaction between said first target and said parent polypeptide involves either binding or catalytic interaction of said parent polypeptide with said first target.

25. The method of claim 24 wherein the activity between said first target and any of said substituted polypeptides is increased greater than two-fold as compared to said parent polypeptide.

26. The method of claim 24 wherein the activity between said first target and any of said substituted polypeptides is decreased greater than two-fold as compared to said parent polypeptide.

27. The method of claim 1 wherein said parent polypeptide is selected from the group consisting of growth hormone, prolactin, placental lactogen,.alpha.-interferon,.gamma.-interferon, TGF-.alpha..sub.1, EGF, IGF-1, GM-CSF, TNF, tissue plasminogen activator, and CD-4 receptor.

28. The method of claim 27 wherein said parent polypeptide is selected from the group consisting of human growth hormone, human placental lactogen, and human prolactin.

29. The method of claim 1 wherein said activity is measured in an in vitro assay.

30. The method of claim 29 wherein said parent polypeptide is a hormone and said activity is measured in an in vitro assay using a soluble hormone receptor.

31. The method of claim 30 wherein said hormone is human growth hormone and said soluble hormone receptor is shGHr.

32. The method of claim 30 wherein said hormone is human growth hormone and said soluble hormone receptor is shPRLr.

33. The method of claim 1 wherein said interaction between said first target and said parent polypeptide involves either binding or catalytic interaction of said parent polypeptide with said first target.

34. The method of claim 33 wherein the activity between said first target and any of said substituted polypeptides is increased greater than two-fold as compared to said parent polypeptide.

35. The method of claim 33 wherein the activity between said first target and any of said substituted polypeptides is decreased greater than two-fold as compared to said parent polypeptide.

36. The method of claim 1, wherein said analog has at least 15% amino acid sequence homology with said parent polypeptide.

37. The method of claim 1, wherein said analog is naturally occurring.

38. The method of claim 1, wherein said analog is a tertiary analog.

39. The method of claim 1 wherein said parent polypeptide is human growth hormone and said analog is selected from the group consisting of human placental lactogen, porcine growth hormone, and human prolactin.

40. The method of claim 1 wherein the biological activity of the parent polypeptide is of clinical utility.

41. The method of claim 1 wherein said parent polypeptide is selected from the group consisting of a hormone, enzyme, antigen, receptor, enzyme substrate, binding protein, and enzyme inhibitor.

42. The method of claim 1 wherein said first target is selected from the group consisting of a hormone, enzyme, antibody, antigen, receptor, enzyme substrate, binding protein, and enzyme inhibitor.

43. The method of claim 1 wherein said analog does not substantially interact with said first target.

44. The method of claim 8 wherein at least one of said scanning amino acids is an isosteric amino acid.

45. The method of claim 8 wherein the same scanning amino acid is employed in steps (f) and (h), and said scanning amino acid is a neutral amino acid.

46. The method of claim 45 wherein said neutral amino acid is selected from the group consisting of alanine, serine, glycine, and cysteine.

47. The method of claim 46 wherein said scanning amino acid is alanine.

48. The method of claim 1 wherein said parent polypeptide is naturally occurring.

49. The method of claim 14 wherein said parent polypeptide is naturally occurring.

Referenced Cited
U.S. Patent Documents
4446235 May 1, 1984 Seeburg
4655160 April 7, 1987 Seeburg
4670393 June 2, 1987 Seeburg
4699897 October 13, 1987 Jones et al.
4732973 March 22, 1988 Borr et al.
4871835 October 3, 1989 Aviv et al.
4888286 December 19, 1989 Crea
5085862 February 4, 1992 Klein et al.
5204244 April 20, 1993 Fell et al.
5350836 September 27, 1994 Kopchick et al.
Foreign Patent Documents
0 089 666 A3 September 1983 EPX
8807578 June 1988 EPX
0 320 308 A2 June 1989 EPX
WO 88/07084 September 1988 WOX
WO 88/07578 October 1988 WOX
Other references
  • Nicoll et al., "Structural Features Of Prolactins and Growth Hormones That Can Be Related to Their Biological Properties", Endocrine Reviews 7:169-203 (1986). Abdel-Maeguid, S. S. et al., "Three-dimensional structure of a genetically engineered variant of porcine growth hormone", 84 Proc. Natl. Acad. Sci. USA 6434-6437 (1987). Bajt et al., Characterization of a Gain of Function Mutation of Integrin .alpha.II.beta.3 (Platelet Glycoprotein IIb-IIIa), 267 J. Biol. Chem. 22211-22216 (1992). Barlow, D. J. et al., "Continuous and discontinuous protein antigenic determinants", 322 Nature 747-748 (1986). Bennett et al., "High Resolution Analysis of Functional Determinants of Human Tissue-type Plasminogen Activator", 266 J. Biol. Chem. 5191-5201 (1991). Berendt et al., "The Binding Site on ICAM-1 for Plasmodium falciparum-Infected Erythrocytes Overlaps, but is Distinct LFA-1 Binding Site", 68 Cell 71-81 (1992). Berlot et al., "Identification of Effector-Activating Residues of G s.alpha.", 68 Cell 911-922 (1992). Bettler et al., "Immunoglobulin E-binding Site in Fc Receptor (FcRII/CD23) Identified by Homolog-scanning Mutagenesis", 267 J. Biol. Chem. 185-191 (1992). Boutin, J. M. et al., "Cloning and Expression of the Rat Prolactin Receptor, a Member of the Growth Hormone/ Prolactin Receptor Gene Family", 53 Cell 69-77 (1988). Burstein et al., "Immunoreactivity and receptor binding of mixed recombinants of human growth hormone and chorionic somatomammotropin", 75 Proc. Natl. Acad. Sci. USA 5391-5394 (1978). Camble, R. et al., "Properties of Interferon-.alpha.2 Analogues Produced from Synthetic Genes in Peptides: Structure and Function", Proceedings of the Ninth American Peptide Symposium 375-384 (Deber et al. eds. 1985). Chang, C. N. et al., "High-level secretion of human growth hormone by Escherichia coli", 55 Gene 189-196 (1987). Clayton et al., "Substitution of murine for human CD4 residues identifies amino acids critical for HIV-gp120 binding", 355 Nature 363-366 (1988). Cunningham, B., "Improvement in the alkaline stability of subtilisin using an efficient random mutagenesis and screening procedure", 108 Chemical Abstracts 11 (1988). Cunningham, B. et al., "Receptor and Antibody Epitopes in Human Growth Hormone Identified by Homolog-Scanning Mutagenesis", 243 Science 1330-1336 (1989). Cunningham, B. et al., "High-Resolution Epitope Mapping of hGH-Receptor Interactions by Alanine-Scanning Mutagenesis", 244 Science 1081-1085 (1989). Ge et al., "Functional Domains of Bacillus thuringiensis Insecticidal Crystal Proteins", 266 J. Biol. Chem. 17954-17958 (1991). Geysen et al., 81 P.N.A.S., USA 3998-4002 (1984). Goeddel et al., "Direct expression in Escherichia coli of a DNA sequence coding for human growth hormone", 281 Nature 544-548 (1979). Gray et al., "Periplasmic production of correctly processed human growth in Escherichia coli: natural and bacterial signal sequences are interchangeable", 39 Gene 247-254 (1985). Hotta et al., 149 Biochem. and Biophys. Res. Comm. 531-537 (1987). Huang et al., 223 FEBS Letters 294-298 (1987). Jones, P. T. et al., "Replacing the complementarity-determining regions in a human antibody with those from a mouse", 321 Nature 522-525 (1986). Kobilka, B. et al., "Chemeric .alpha.2-,.beta.2-Adrenergic Receptors: Delineation of Domains Involved in Effector Coupling and Ligand Binding Specificity", 240 Science 1310-1316 (1988). Kostyo, J. L. et al., "Biological characterization of purified native 20-kDa human growth hormone", 925 Biochemica et Biophysica Acta 314 (1987). Krivi, G. G. et al., "Immunohistochemical Expression of Insulin-like growth factor I during Skeletal Muscle Regeneration in Normal . . . ", Abstract I-18, Int'l. Symp. on Growth Hormone; Basic and Clin. Aspects, Final Program, sponsored by Serono Symposia, USA (Jun. 14-18, 1987). Laskowski, M. et al., "Positive Darwinian Selection in Evolution of Protein Inhibitors of Serine Proteinases", 52 Cold Spring Harbor Symp. Quant. Biol. 545 (1987). Leung, D. W. et al., "Growth hormone receptor and serum binding protein: purification, cloning and expression", 330 Nature 537-543 (1987). Lewis, U. J. et al., "A Naturally Occurring Structural Variant of Human Growth Hormone", 253 J. Biol. Chem. 2679-2687 (1978). Lewis, U. J., "Variants of Growth Hormone and Prolactin and Their Posttranslational Modifications", 46 Ann. Rev. Physiol. 33-42 (1984). Li, C. H., "Human growth hormone: 1974-1981", 46 Mol. Cell. Biochem. 31-41 (1982). Marseigne et al., 31 J. Med. Chem. 966-970 (1988). Mills, J. B. et al., "Fragments of Human Growth Hormone Produced by Digestion with Thrombin: Chemistry and Biological Properties", 107 Endocrinology 391-399 (1980). Nakashima et al., "Alanine-scanning Mutagenesis of the Epidermal Growth Factor-like Domains of Human Thrombomodulin Identifies Critical Residues for Its Cofactor Activity", 268 J. Biol. Chem. 2888-2892 (1993). Russell et al., "Recombinant Hormones from Fragments of Human Growth Hormone and Human Placental Lactogen", 256 J. Biol. Chem. 296-300 (1981). Seeberg, P. H., "The Human Growth Hormone Gene Family: Nucleotide Sequences Show Recent Divergence and Predict a New Polypeptide Hormone", 1 DNA 239-249 (1982). Sourouton, M. C. et al., "Localization of Highly Immunogenic Region on the Acetylcholine Receptor Alpha-Subunit", 135 Biochem. Biophys. Res. Commun. 82-89 (1986). Tokunaga, T. et al., "Synthesis and expression of a human growth hormone (somatotropin) gene mutated to change cysteine-165 to alanine", 153 Eur. J. Biochem. 445-449 (1985). Venuti et al., "The Impact of Biotechnology on Drug Discovery", Ann. Reports in Medicinal Chem. 289-298 (Vinick ed. 1989). Wells, J., "Systematic Mutational Analysis of Protein-Protein Interfaces", 202 Methods in Enzymology 390-411 (1991). Werther et al., "Localization and Characterization of Insulin Receptors in Rat Brain and Pituitary Gland Using In-Vitro Autoradiography and Computerized Densitometry", 121 Endocrinol. 1562-1570 (1987). Wertman et al., "Systematic Mutational Analysis of the Yeast ACT1 Gene", 132 Genetics 337-350 (1992). Wharton, R. P. et al., "Substituting an .alpha.-Helix Switches the Sequence-Specific DNA Interactions of a Repressor", 38 Cell 361-369 (1984). Wharton, R. P. et al., "Changing the binding specificity of a repressor by redesigning an .alpha.-helix", 316 Nature 601-605 (1985). Wharton, R. P. et al., 38 Nature 316-369 (1985). Wu and Wallace, "The Ligation Amplification Reaction (LAR)--Amplification of Specific DNA Sequences Using Sequential Rounds of Template-Dependent Ligation", 4 Genomics 560-569 (1989). Zhang et al., "Toward a Simplification of the Protein Folding Problem: A Stablizing Polyalanine .alpha.-Helix Engineered in T4 Lysozyme", 30 Biochemistry 2012-2017 (1991). Zoller et al., "New molecular biology methods of protein engineering", 1 Current Opinion in Structural Biology 605-610 (1991).
Patent History
Patent number: 5766854
Type: Grant
Filed: Jun 6, 1995
Date of Patent: Jun 16, 1998
Assignee: Genentech, Inc. (San Francisco, CA)
Inventors: James A. Wells (Burlingame, CA), Brian C. Cunningham (Piedmont, CA)
Primary Examiner: Ponnathapura Achutamurthy
Attorneys: Skjerven, Morrill, MacPherson, Franklin & Friel, LLP, Skjerven, Morrill, MacPherson, Franklin & Friel, LLP
Application Number: 8/483,039
Classifications
Current U.S. Class: 435/6; 435/71; 435/691; 435/711; Biospecific Ligand Binding Assay (436/501); 530/3871; 530/3881; Hormones, E.g., Prolactin, Thymosin, Growth Factors, Etc. (530/399); Antigenic Peptides Or Proteins (530/806); Materials And Products Related To Genetic Engineering Or Hybrid Or Fused Cell Technology, E.g., Hybridoma, Monoclonal Products, Etc. (530/808); 935/10; 935/11; 935/12; 935/13; 935/14; 935/15; 935/76; 935/77; 935/82
International Classification: C12Q 168; G01N 33566; C07K 1600; C12N 1500;